Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD L 506 iPDT in newly diagnosed IDH wild-type glioblastoma
2023-510024-79-00Phase 2Completed
- Sponsor
- photonamic GmbH & Co. KG
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by photonamic GmbH & Co. KG. Primary endpoint: Treatment-emergent grade 3–5 adverse events within two weeks following iPDT. Started Jul 2024; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-510024-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510024-79-00.